Oral News and Research

RSS

HealthCore study reports that oral controllers provide better clinical outcomes for asthma patients

Mayo Clinic Proceedings published a peer-reviewed comparative effectiveness study performed by HealthCore, Inc. in its August edition. The study demonstrated that in general had better clinical outcomes with oral controllers than inhaled corticosteroids.

26 Aug 2009

Importance of access to oral health care emphasized

Kool Smiles, a leading general dentistry provider for kids and parents, opened the doors to its newest location in the Bashford area of Louisville, KY.

26 Aug 2009

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).

26 Aug 2009

Sabril (vigabatrin) Oral Solution receives approval from FDA

Sabril (vigabatrin) Oral Solution has been approved by the U.S. Food and Drug Administration to treat infantile spasms in children ages 1 month to 2 years. Sabril is the first drug in the United States approved to treat the disorder, characterized by a severe type of seizure that usually appears in the first year of life, typically between ages 4 months and 8 months.

26 Aug 2009

FDA issues warning letters to eight companies for selling illegal OTC ibuprofen drugs

The U.S. Food and Drug Administration today announced that the agency issued warning letters to eight companies marketing unlawful over-the-counter (OTC) topical drug products containing the pain reliever ibuprofen.

26 Aug 2009

MicroRNAs in saliva could aid in the detection of oral cancer

Researchers continue to add to the diagnostic alphabet of saliva by identifying the presence of at least 50 microRNAs that could aid in the detection of oral cancer, according to a report in Clinical Cancer Research, a journal of the American Association for Cancer Research.

26 Aug 2009

Venlafaxine alleviates depressive symptoms

The Institute for Quality and Efficiency in Health Care (IQWiG) was commissioned by the Federal Joint Committee (G-BA) to investigate whether patients with depression benefit from taking drugs belonging to the selective serotonin and norepinephrine reuptake inhibitor (SNRI) drug class.

25 Aug 2009

MicroRNAs present in saliva could be used to detect oral squamous cell carcinoma

A new study published by researchers at the UCLA School of Dentistry substantiates the effectiveness of measuring the microRNAs present in saliva to detect oral squamous cell carcinoma. Like hall monitors in an elementary school, microRNAs are the molecules produced by cells that simultaneously asses the behavior of multiple genes and control their activity.

25 Aug 2009

QSI Dental Division's forges Channel Partner agreement with NEA

Quality Systems, Inc. announced today that its dental division (QSI Dental Division) has entered into a Channel Partner agreement with National Electronic Attachment, Inc. (NEA), a leading provider in the transmission of supporting documentation and attachments for electronic claims to payors for reimbursement purposes.

25 Aug 2009

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that study results demonstrated that arimoclomol exhibited both statistically significant neuroprotective and neuroregenerative effects in brain cells of animals induced with stroke, offering important insights into this drug candidate’s mechanism of action.

25 Aug 2009

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

Portola Pharmaceuticals, Inc. today announced two oral presentations at the European Society of Cardiology (ESC) Congress 2009 in Barcelona, Spain, that will feature its investigational antiplatelet drug elinogrel, a P2Y12 ADP receptor antagonist that is currently in Phase II clinical development with Novartis, Portola's development and commercialization partner.

25 Aug 2009

Nutra Pharma submits final packaging and labeling for Cobroxin drug for FDA approval

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully submitted final packaging and labeling to the Food and Drug Administration (FDA) to begin selling Cobroxin, an over-the-counter (OTC) treatment for stage 2 (moderate to severe) chronic pain.

25 Aug 2009

New study reveals that mild glucose intolerance in pregnancy may relate to risk of heart disease

Mild glucose intolerance in pregnancy may be an early identifier of women who are at increased risk of heart disease in the future, found a new study http://www.cmaj.ca/press/cmaj090569.pdf published in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

25 Aug 2009

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements.

25 Aug 2009

UCB and sanofi-aventis U.S. receive FDA's approval for XYZAL to treat allergies in children

UCB and sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved XYZAL(R) (levocetirizine dihydrochloride) for children age six months and older for the relief of symptoms of perennial allergic rhinitis (indoor allergies) and chronic idiopathic urticaria (chronic hives) and for children age two years and older for symptoms of seasonal allergic rhinitis (outdoor allergies).

25 Aug 2009

NIAID funds Nanotherapeutic for developing an inhaled version of the injectable antiviral drug

Nanotherapeutics, Inc., today announced that it has been awarded a $30.9 Million, 5-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop an inhaled version of the injectable antiviral drug, cidofovir, for non-invasive, post-exposure prophylaxis and treatment of the Category A bioterrorism agent smallpox (Variola major).

25 Aug 2009

P&G's global pharmaceuticals business sold to Warner Chilcott for $3.1 billion

The Procter & Gamble Company and Warner Chilcott plc today announced an agreement for the sale of P&G's global pharmaceuticals business to Warner Chilcott for an up-front cash payment of $3.1 billion.

24 Aug 2009

$25.7 million in grants announced to increase and improve US health center services

Health and Human Services Secretary Kathleen Sebelius today announced more than $25.7 million in grants to increase and improve health and support services at the nation's health centers.

24 Aug 2009

Diabetics can reduce the risk of cardiovascular disease by increasing vitamin D levels

Low levels of vitamin D are known to nearly double the risk of cardiovascular disease in patients with diabetes, and researchers at Washington University School of Medicine in St. Louis now think they know why.

24 Aug 2009

Lundbeck to launch Sabril in the US following FDA's NDA approval

Lundbeck Inc. (“Lundbeck”), a wholly owned subsidiary of H. Lundbeck A/S in Denmark (Copenhagen: LUN), announced today that the U.S. Food and Drug Administration (FDA) has granted two New Drug Application (NDA) approvals for Sabril® (vigabatrin) Tablets and Oral Solution. Lundbeck plans to launch Sabril in the United States in the third quarter.

24 Aug 2009

Oral News and Research

HealthCore study reports that oral controllers provide better clinical outcomes for asthma patients

Importance of access to oral health care emphasized

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Sabril (vigabatrin) Oral Solution receives approval from FDA

FDA issues warning letters to eight companies for selling illegal OTC ibuprofen drugs

MicroRNAs in saliva could aid in the detection of oral cancer

Venlafaxine alleviates depressive symptoms

MicroRNAs present in saliva could be used to detect oral squamous cell carcinoma

QSI Dental Division's forges Channel Partner agreement with NEA

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

Nutra Pharma submits final packaging and labeling for Cobroxin drug for FDA approval

New study reveals that mild glucose intolerance in pregnancy may relate to risk of heart disease

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

UCB and sanofi-aventis U.S. receive FDA's approval for XYZAL to treat allergies in children

NIAID funds Nanotherapeutic for developing an inhaled version of the injectable antiviral drug

P&G's global pharmaceuticals business sold to Warner Chilcott for $3.1 billion

$25.7 million in grants announced to increase and improve US health center services

Diabetics can reduce the risk of cardiovascular disease by increasing vitamin D levels

Lundbeck to launch Sabril in the US following FDA's NDA approval

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News